These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6891988)

  • 1. Pre- and post-synaptic dopaminergic receptors involved in apomorphine-induced yawning.
    Urba-Holmgren R; Holmgren B; Anias J
    Acta Neurobiol Exp (Wars); 1982; 42(2):115-25. PubMed ID: 6891988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Age-related modification of dopaminergic-cholinergic neuronal interaction in rats].
    Kishimoto O
    Yakubutsu Seishin Kodo; 1988 Dec; 8(4):443-51. PubMed ID: 3250156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of apomorphine-, physostigmine- and pilocarpine-induced yawning after long-term treatment with neuroleptic or cholinergic agents.
    Ushijima I; Noda Y; Mizuki Y; Yamada M
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):180-8. PubMed ID: 6150689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological and behavioral assessments of dopamine autoreceptor activation to apomorphine in rats.
    Okuyama S; Shimamura H; Hashimoto S; Aihara H
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):246-54. PubMed ID: 3827410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two distinctive apomorphine-induced phenotypes in the Roman high- and low-avoidance rats.
    Giménez-Llort L; Cañete T; Guitart-Masip M; Fernández-Teruel A; Tobeña A
    Physiol Behav; 2005 Nov; 86(4):458-66. PubMed ID: 16154604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cholinergic and dopaminergic influences on yawning behavior.
    Holmgren B; Urbá-Holmgren R
    Acta Neurobiol Exp (Wars); 1980; 40(3):633-42. PubMed ID: 6969021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
    Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of bifemelane on central dopaminergic and cholinergic systems in rats].
    Ushijima I; Tsutsumi C; Hara T; Soeda K; Kishimoto O; Kaneyuki H; Mizuki Y; Yamada M
    Yakubutsu Seishin Kodo; 1988 Dec; 8(4):463-70. PubMed ID: 2907957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the action of (+/-)sulpiride on dopamine receptors in the rat brain in vivo.
    Hasan F; Leonard BE
    Neuropharmacology; 1981 Dec; 20(12B):1327-30. PubMed ID: 7198724
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
    Timar J; Knoll B; Knoll J
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):255-66. PubMed ID: 3103558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M; White FJ
    Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE; Grabowska-Andén M
    Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine.
    Ushijima I; Mizuki Y; Imaizumi J; Yamada M; Noda Y; Yamada K; Furukawa T
    Arch Int Pharmacodyn Ther; 1985 Feb; 273(2):196-201. PubMed ID: 4004417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning.
    Yamada K; Furukawa T
    Psychopharmacology (Berl); 1980 Jan; 67(1):39-43. PubMed ID: 6768077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats.
    Protais P; Dubuc I; Costentin J
    Eur J Pharmacol; 1983 Oct; 94(3-4):271-80. PubMed ID: 6140175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic and nicotinic effects on yawning and tongue protruding in the rat.
    Ushijima I; Yamada K; Inoue T; Tokunaga T; Furukawa T; Noda Y
    Pharmacol Biochem Behav; 1984 Aug; 21(2):297-300. PubMed ID: 6541344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.